Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:1225.

N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells

Arturo Contis-Montes de Oca, Estefanía Rodarte-Valle, Martha Cecilia Rosales-Hernández, Edgar Abarca-Rojano _, Saúl Rojas-Hernández, Manuel Jonathan Fragoso-Vázquez, Jessica Elena Mendieta-Wejebe, Ana María Correa-Basurto, Ismael Vázquez-Moctezuma and José Correa-Basurto

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:33368-33381. https://doi.org/10.18632/oncotarget.26077

Metrics: PDF 666 views  |   HTML 1438 views  |   ?  


Abstract

Arturo Contis-Montes de Oca1,*, Estefanía Rodarte-Valle2,*, Martha Cecilia Rosales-Hernández2, Edgar Abarca-Rojano3, Saúl Rojas-Hernández1, Manuel Jonathan Fragoso-Vázquez4, Jessica Elena Mendieta-Wejebe2, Ana María Correa-Basurto2, Ismael Vázquez-Moctezuma2 and José Correa-Basurto2,5

1Laboratorio de Inmunobiología Molecular y Celular, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

2Laboratorio de Biofísica y Biocatálisis, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

3Laboratorio de Respiración Celular, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

4Departamento de Química Orgánica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México

5Laboratorio de Modelado Molecular y Bioinformática y Diseño de Fármacos, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

*These authors contributed equally to this work

Correspondence to:

Edgar Abarca Rojano, email: rojanoe@yahoo.com

José Correa Basurto, email: corrjose@gmail.com

Keywords: histone deacetylase inhibitors; high-mobility group box 1 protein; reactive oxygen species; valproic acid derivatives; OH-VPA

Received: December 27, 2017     Accepted: August 21, 2018     Published: September 07, 2018

ABSTRACT

N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA) is a valproic acid (VPA) derivative with improved antiproliferative activity toward breast cancer (MCF-7, MDA-MB-231, and SKBr3) and human cervical cancer cell lines (HeLa) compared to that of VPA. However, the pharmacological mechanism of OH-VPA activity remains unknown. High-mobility group box 1 (HMGB1) is an important enzyme that is highly expressed in tumor cells and has a subcellular localization that is dependent on its acetylation or oxidative state. Therefore, in this study, we analyzed changes in HMGB1 sub-cellular localization and reactive oxygen species (ROS) as well as changes in HeLa cell viability in response to treatment with various concentrations of OH-VPA. This compound is formed by the covalent bond coupling VPA to a phenol group, which is capable of acting as a free radical scavenger due to its chemical similarities to quercetin. Our results show that OH-VPA induces nuclear to cytoplasmic translocation of HMGB1, as demonstrated by confocal microscopy observations and infrared spectra that revealed high quantities of acetylated HMGB1 in HeLa cells. Cells treated with 0.8 mM OH-VA exhibited decreased viability and increased ROS levels compared with the lower OH-VPA concentrations tested. Therefore, the antiproliferative mechanism of OH-VPA may be related to histone deacetylase (HDAC) inhibition, as is the case for VPA, which promotes high HMBG1 acetylation, which alters its subcellular localization. In addition, OH-VPA generates an imbalance in cellular ROS levels due to its biochemical activity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26077